Novartis Pharma AG: Novartis Scemblix demonstrates sustained

Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix (asciminib) vs. Bosulif* (bosutinib) and lower discontinuation rate due to adverse

Related Keywords

United States , East Hanover , Pennsylvania , Philadelphia , America , American , Isabella Zinck , Jeff Legos , Thomas Hungerbuehler , Floriana Riccio Furnari , Michaelj Mauro , Samir Shah , Parag Mahanti , Julie Masow , Sloan Simpson , Alina Levchuk , Novartis Oncology Congress Hub , Twitter , Novartis Oncology Communications , Novartis Us External Communications , Novartis External Communications , Novartis , Exchange Commission , Pfizer , Approval Program , American Society Of Hematology Annual Meeting Exposition , Novartis Pharmaceuticals Corp , American Society , Hematology Annual Meeting , Myeloproliferative Neoplasms Program Leader , Memorial Sloan Kettering Cancer Center , Executive Vice President , Global Head , Hematology Development , Novartis Commitment , Prescribing Information , Safety Results , Chronic Myeloid Leukemia , Chronic Phase , Tyrosine Kinase Inhibitors , Randomized Study , Provides Durable Molecular Response , Primary Efficacy , Allosteric Inhibitor , Tyrosine Kinase Activity , Reveals Significant , Durable Responses , Exhibits Safety , Phasei Study , Asciminib Plus Nilotinib , Therapy Using Asciminib Plus Imatinib , Previously Treated With , Adult Patients With Newly Diagnosed , More Tyrosine Kinase , Patients With , Pediatric Patients With Chronic Myeloid Leukemia , Treatment Optimization , Open Label , Once Daily , Newly Diagnosed Adult Patients , Pediatric Patients , Chronic Phase Treated , Tyrosine Kinase , Dharma , Scemblix , Emonstrates , Sustained , Response , Gate , Eek , Follow , Patients , Hronic , Amyeloid , Leukemia ,